{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"48","value":"14.97"},{"groupId":"OG001","spread":"73","value":"14.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37","value":"22.54"},{"groupId":"OG001","spread":"84","value":"20.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"53","value":"23.55"},{"groupId":"OG001","spread":"60","value":"23.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"41","value":"23.58"},{"groupId":"OG001","spread":"186","value":"19.32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36","value":"29.67"},{"groupId":"OG001","spread":"249","value":"17.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36","value":"29.01"},{"groupId":"OG001","spread":"30","value":"29.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"title":"Cycle 9 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16","value":"34.29"},{"groupId":"OG001","spread":"770","value":"12.74"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22","value":"40.90"},{"groupId":"OG001","spread":"56","value":"22.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 15 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25","value":"35.09"},{"groupId":"OG001","spread":"75","value":"20.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Cycle 18 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25","value":"27.16"},{"groupId":"OG001","spread":"55","value":"22.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Cycle 21 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16","value":"30.81"},{"groupId":"OG001","spread":"38","value":"38.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 24 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33","value":"43.62"},{"groupId":"OG001","spread":"32","value":"35.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Follow-up Day 28"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Trough PF-06801591 Concentrations (Ctrough) - Part 2. Ctrough was directly observed from data.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with NSCLC received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 851 days)","id":"OG000","title":"Part 2: PF-06801591 300 mg (SC) for NSCLC"},{"description":"Participants with UC received PF- 06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 841 days)","id":"OG001","title":"Part 2: PF-06801591 300 mg (SC) for UC"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Analysis population included all participants who received PF-06801591, had no protocol deviations affecting the pharmacokinetics (PK) assessment, and had at least 1 post-dose concentration measurement above lower limit of quantification.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 1 of Cycles 2-6, 9, 12, 15, 18, 21, 24, and Follow-up Day 28 in Part 2","title":"Trough PF-06801591 Concentrations (Ctrough) - Part 2","type":"SECONDARY","unitOfMeasure":"ug/mL"}